MENU
+Compare
INTS
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$2.76
Change
-$0.01 (-0.36%)
Capitalization
41.69M

INTS Intensity Therapeutics Forecast, Technical & Fundamental Analysis

Industry Biotechnology
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for INTS with price predictions
Jan 14, 2025

INTS's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for INTS turned positive on January 02, 2025. Looking at past instances where INTS's MACD turned positive, the stock continued to rise in of 12 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on January 08, 2025. You may want to consider a long position or call options on INTS as a result. In of 33 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

INTS moved above its 50-day moving average on January 14, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where INTS advanced for three days, in of 64 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INTS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

INTS broke above its upper Bollinger Band on January 10, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for INTS entered a downward trend on January 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INTS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.993) is normal, around the industry mean (14.746). P/E Ratio (0.000) is within average values for comparable stocks, (87.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.852). INTS has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (263.573).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INTS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
INTS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

INTS is expected to report earnings to fall 9.00% to -22 cents per share on March 13

Intensity Therapeutics INTS Stock Earnings Reports
Q4'24
Est.
$-0.23
Q3'24
Beat
by $0.06
Q2'24
Missed
by $0.04
Q4'23
Missed
by $0.05
Q3'23
Missed
by $0.08
The last earnings report on November 13 showed earnings per share of -25 cents, beating the estimate of -30 cents. With 27.02K shares outstanding, the current market capitalization sits at 41.69M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1 Enterprise Drive
Phone
+1 203 221-7381
Employees
17
Web
https://www.intensitytherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
CRYPTO / NAMEPrice $Chg $Chg %
BTC.X104462.0400004705.133000
+4.72%
Bitcoin cryptocurrency
TSLA426.5012.68
+3.06%
Tesla
SPY597.585.94
+1.00%
SPDR® S&P 500® ETF Trust
AAPL229.981.72
+0.75%
Apple
GME27.51-0.21
-0.76%
GameStop Corp

INTS and Stocks

Correlation & Price change

A.I.dvisor tells us that INTS and GBIO have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INTS and GBIO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INTS
1D Price
Change %
INTS100%
-0.36%
GBIO - INTS
29%
Poorly correlated
+0.18%
MRKR - INTS
29%
Poorly correlated
-7.52%
ACAD - INTS
28%
Poorly correlated
+0.29%
SYRE - INTS
28%
Poorly correlated
+0.34%
GPCR - INTS
27%
Poorly correlated
+0.30%
More